In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Looking ahead to 2025, Sandoz said it expects net sales to grow by a mid-single digit percentage in constant currencies.

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

As a medication vital for improving patient outcomes, Humira's high cost presents employers with the challenge of balancing financial considerations with the opportunities offered by biosimilars ...